[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-CSN-030626190--":3,"related-articles-undefined-undefined-3b0c143a-1ddd-4edc-8eae-c9192ac88aac-true":15},{"id":4,"type":5,"title":6,"pubDate":7,"logoUrl":8,"anpFeedCategory":9,"organisationTitle":10,"thirdParty":11,"body":12,"orgId":13,"description":14},"CSN-030626190","PRESSRELEASE"," RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak","2026-06-03T18:06:22.000+02:00","https:\u002F\u002Fwww.persberichten.nl\u002Fimg\u002Fpr-newswire.png","Economie","PR Newswire",true,"\u003Cp> TEL AVIV, Israel and RALEIGH, N.C., June 3, 2026 \u002FPRNewswire\u002F -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (\"RedHill\" or the \"Company\"), a specialty biopharmaceutical company, today announced that it is actively discussing potential collaborations for advancement of its investigational oral drug, opaganib, to combat EVD, which can be fatal in approximately half of all cases, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platform and pharma collaborations.\u003C\u002Fp>\u003Cp> \"Opaganib sits in a distinct category as a host-directed agent which can be added to direct-acting antivirals, representing an opportunity to enhance global infectious disease preparedness and biodefense infrastructure against EVD, while also being preferentially suited to the logistical challenges found on the ground during these tragic outbreaks.\"\u003C\u002Fp>\u003Cp> Peer-reviewed data shows opaganib's host-direction action stems from its ability to simultaneously inhibit three sphingolipid-metabolizing enzymes in human cells (SPHK2, DES1 and GCS), altering the cellular lipid balance and enabling inhibition of replication of viruses like SARS-CoV-2 and Ebola. In EVD specifically, opaganib offers a potential dual mechanism of action; blocking the PI3K\u002FAkt pathway critical for filovirus entry and suppressing NLRP3 inflammasome and reducing IL-6\u002FTNFα and S1P-mediated vascular permeability (addressing immune dysregulation and vascular leak).\u003C\u002Fp>\u003Cp> Proactively, and upon request, the Company has provided information to relevant government, industry and other organizations, regarding supply readiness and all available clinical and preclinical safety and efficacy data to aid rapid clinical and regulatory discussions.\u003C\u002Fp>\u003Cp> Opaganib has demonstrated its safety and tolerability profile in more than 470 participants in multiple clinical studies and expanded access use, including a large global Phase 2\u002F3 study in hospitalized patients with moderate to severe COVID-19, published in . Opaganib is an investigational new drug. It has not been approved by any regulatory authority and is not available for commercial distribution. Inclusion in the WHO CORE platform cannot be guaranteed.\u003C\u002Fp>\u003Cp> RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology.\u003C\u002Fp>\u003Cp> Visit  \u002F  for more information about the Company\u003C\u002Fp>\u003Cp> Adi FrishChief Corporate & Business Development OfficerRedHill Biopharma\u003C\u002Fp>\u003Cp> Category: R&D\u003C\u002Fp>\u003Cp> Opaganib is an investigational new drug, not available for commercial distribution.\u003C\u002Fp>\u003Cp> Neuenschwander FC, Barnett-Griness O, Piconi S, Maor Y, Sprinz E, Assy N, Khmelnitskiy O, Lomakin NV, Goloshchekin BM, Nahorecka E, et al. Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Based upon FIO2 Requirements. Microorganisms. 2024; 12(9):1767.\u003C\u002Fp>\u003Cp> Antiviral Activity of Opaganib, a First-in-class Sphingolipid Modulator. Rekha G. Panchal1*, Raina Kumar1, Eric Nguyen1#, LTC Jeffrey Kugelman1, Janet Skerry1, Xiaoli Chi1, Ashley Mcaleese1#, Aura R. Garrison, Mark Levitt, Gilead Raday, Patricia Anderson, Sara Johnston, Reza Fathi, LTC Robert Haupt United States Army Medical Research Institute of Infectious Diseases\u003C\u002Fp>\u003Cp> Repeat study showed 20% vehicle survival vs. 10% opaganib; mixed results across the two animal models (including the vehicle only group inter study variability) underscore model variability.\u003C\u002Fp>\u003Cp> Sphingosine Kinases Promote Ebola Virus Infection and Can Be Targeted to Inhibit Filoviruses, Coronaviruses, and Arenaviruses Using Late Endocytic Trafficking to Enter Cells. Corina M. Stewart, Yuxia Bo, Kathy Fu, Mable Chan, Robert Kozak, Kim Yang-Ping Apperley, Geneviève Laroche, Redaet Daniel, André M. Beauchemin, Gary Kobinger, Darwyn Kobasa, and Marceline Côté. ACS Infectious Diseases 2023 9 (5), 1064-1077. DOI: 10.1021\u002Facsinfecdis.2c00416\u003C\u002Fp>\u003Cp> Sphingosine Kinases Promote Ebola Virus Infection and Can Be Targeted to Inhibit Filoviruses, Coronaviruses, and Arenaviruses Using Late Endocytic Trafficking to Enter Cells. Corina M. Stewart, Yuxia Bo, Kathy Fu, Mable Chan, Robert Kozak, Kim Yang-Ping Apperley, Geneviève Laroche, Redaet Daniel, André M. Beauchemin, Gary Kobinger, Darwyn Kobasa, and Marceline Côté. ACS Infectious Diseases 2023 9 (5), 1064-1077. DOI: 10.1021\u002Facsinfecdis.2c00416\u003C\u002Fp>\u003Cp> Logo:\u003C\u002Fp>\u003Cp> View original content: https:\u002F\u002Fwww.prnewswire.co.uk\u002Fnews-releases\u002Fredhill-biopharma-advancing-opaganib-options-for-ebola-virus-disease-outbreak-302790437.html\u003C\u002Fp>","3b0c143a-1ddd-4edc-8eae-c9192ac88aac","TEL AVIV, Israel and RALEIGH, N.C., June 3, 2026 \u002FPRNewswire\u002F -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (\"RedHill\" or the \"Company\"), a specialty biopharmaceutic",[16,21,26,31,36,41,46,51,56,61],{"id":17,"title":18,"pubDate":19,"logoUrl":8,"thirdParty":11,"orgId":13,"description":20},"CSN-171126208"," Clapp Finance lanceert Corporate Crypto Credit Lines: cryptoleningen voor bedrijven vanaf 1% JKP","2026-11-17T20:47:25.000+01:00","PRAAG, 17 november 2026 \u002FPRNewswire\u002F -- Clapp Finance heeft vandaag Corporate Crypto Credit Lines aangekondigd, een nieuwe manier voor bedrijven om werkkapitaal",{"id":22,"title":23,"pubDate":24,"logoUrl":8,"thirdParty":11,"orgId":13,"description":25},"CSN-171126197"," Microsoft and organizations across industries launch AI Transparency Initiative to strengthen enterprise trust in AI models and agents","2026-11-17T19:32:25.000+01:00","Through the new AI Transparency Initiative, Microsoft is working with more than 40 organizations, including Accenture, Adobe, KPMG, Mastercard and Volvo Cars, t",{"id":27,"title":28,"pubDate":29,"logoUrl":8,"thirdParty":11,"orgId":13,"description":30},"CSN-171126195"," NNS declares offer for OCI unconditional","2026-11-17T19:19:25.000+01:00","- 9.95% of the Shares have been tendered under the Offer. - All Offer Conditions have been satisfied. - Settlement will take place on 20 November 2026 and follo",{"id":32,"title":33,"pubDate":34,"logoUrl":8,"thirdParty":11,"orgId":13,"description":35},"CSN-171126177"," Bitmine Immersion Technologies (BMNR) maakt bekend dat zijn ETH-bezit 6,08 miljoen tokens bedraagt en dat de totale waarde van zijn cryptobezitti","2026-11-17T16:57:25.000+01:00","Bitmine bezit 4,97% van het totale aanbod van ETH-munten van 122,2 miljoen Bitmine heeft in slechts 15 maanden 99% van de weg naar de 'Alchemy of 5%' afgelegd B",{"id":37,"title":38,"pubDate":39,"logoUrl":8,"thirdParty":11,"orgId":13,"description":40},"CSN-171126161"," Boyuan Capital sluit tweede fonds van 1,1 miljard RMB definitief af, met focus op industriële AI en internationalisering","2026-11-17T16:08:25.000+01:00","SHANGHAI, 17 november 2026 \u002FPRNewswire\u002F -- Boyuan Capital heeft de definitieve afsluiting van zijn tweede fonds (Fund II) afgerond, met een omvang van ongeveer ",{"id":42,"title":43,"pubDate":44,"logoUrl":8,"thirdParty":11,"orgId":13,"description":45},"CSN-171126159"," BoomerangFX Launches ChatGPT AI Search Advertising for Aesthetic, Wellness and Private-Pay Healthcare Practices, Powered by AUVIA™ AI Clinic Co-P","2026-11-17T16:04:25.000+01:00","New offering connects paid search advertising on OpenAI's ChatGPT with AI search optimization for Claude and Gemini, linking lead generation, conversion, practi",{"id":47,"title":48,"pubDate":49,"logoUrl":8,"thirdParty":11,"orgId":13,"description":50},"CSN-171126145"," Danske Bank Fair Fund opent claimprocedure voor compensatie van in aanmerking komende beleggers in ADR's en gewone aandelen van Danske.","2026-11-17T15:18:25.000+01:00","WASHINGTON, 17 november 2026 \u002FPRNewswire\u002F -- RCB Fund Services, LLC, de distributieagent voor het Danske Bank A\u002FS (\"Danske\") Fair Fund (het \"Danske Bank Fair Fu",{"id":52,"title":53,"pubDate":54,"logoUrl":8,"thirdParty":11,"orgId":13,"description":55},"CSN-171126141"," Pujiang Innovation Forum 2026 Brain-Computer Interface Conference Comes to Shanghai This December, Inviting You to Discover China's Complete BCI ","2026-11-17T15:13:25.000+01:00","SHANGHAI, Nov. 17, 2026 \u002FPRNewswire\u002F -- BCI New Voices, a platform serving the BCI supply chain, will organize the Pujiang Innovation Forum 2026 Brain-Computer ",{"id":57,"title":58,"pubDate":59,"logoUrl":8,"thirdParty":11,"orgId":13,"description":60},"CSN-171126138"," Gene2Cure Foundation and Viralgen collaborate to advance a portfolio of gene therapy programs for rare and ultra-rare genetic conditions","2026-11-17T15:05:24.000+01:00","Collaboration brings together Gene2Cure's portfolio development capabilities and Viralgen's proprietary Aava™ platform to support the efficient progression of p",{"id":62,"title":63,"pubDate":64,"logoUrl":8,"thirdParty":11,"orgId":13,"description":65},"CSN-171126136"," Lionel Gelber Prize Board appoints jury of experts to choose winner for 2027","2026-11-17T15:03:25.000+01:00","Annual non-fiction book prize awarded to the best English-language book about international issues TORONTO, Nov. 17, 2026 \u002FPRNewswire\u002F -- The Lionel Gelber Priz"]